Friday, December 30, 2016 5:45:32 PM
I hope other investments in 2017 treat HDC shareholders better than HDC has treated us over the years. It's hard to fathom that we would be ending the year with the stock price at .013, particularly with Neo having commercialized the prostate test. This doesn't seem plausible, but HDC has proven that it can do anything to disappoint.
Since the company has indicated that it will run out of money by the end of Q1, it should be interesting to see if they quietly turn out the lights, or issue a less-than-credible announcement about suing Neo for not providing HDC with royalties. In any event, since Neo hasn't issued a press release on a test that they invested handsomely in, my guess is that they came to realize the test isn't going to be a game changer after all.
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM